IPHA
Innate Pharma
IPHA
IPHA
8 hedge funds and large institutions have $491K invested in Innate Pharma in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
$260K |
| 2 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
$131K |
Top Sellers
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
$63.6K |
| 2 |
Millennium Management
New York
|
$33.6K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
$560 |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $260K | +$134K | +47,754 | +106% |
|
|
ETC
2
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| $131K | +$33.3K | +11,890 | +34% |
|
|
3
Optiver Holding
Amsterdam,
Netherlands
| $63.6K | -$469K | -167,514 | -88% |
|
|
4
Millennium Management
New York
| $33.6K | -$97.9K | -34,971 | -74% |
|
5
Barclays
London,
United Kingdom
| $1K | – | – | – |
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $574 | – | – | – |
|
|
SPIA
7
Steward Partners Investment Advisory
New York
| $560 | -$840 | -300 | -60% |
|
8
UBS Group
Zurich,
Switzerland
| $409 | – | – | – |
|